MS and Demyelinating Disorders

Increases in physical, emotional, and cognitive functioning were more common in patients receiving natalizumab than in patients receiving other disease modifying therapies.

The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.

Evobrutinib, a highly selective BTK inhibitor for the treatment of relapsing multiple sclerosis, showed long-term safety and success in reducing annualized relapse rates.

The Genentech agent, which is approved for patients with relapsing-remitting multiple sclerosis, showed no new safety signals in a comparison between conventional and shorter infusion times.

Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.

Plasma neurofilament light chain (pNfL) may serve as a prognostic tool to assess the risk of developing permanent disability in multiple sclerosis.

The professor of neurology at NYU Langone shares her thoughts on the clinical data that has been released so far on patients with COVID-19.

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic detailed the need to incorporate interdisciplinary care and behavioral medicine in commonplace MS practice.

Neurology News Network for the week ending May 23, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 22, 2020.

The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.